Mike Thompson, MD, PhD, FASCO

Whole Genome Sequencing [WGS] Reveals Novel, Clinically Relevant Biomarkers Missed by Standards of Care for Pts w/ Myelodysplastic Syndrome [MDS] [Jun 11, 2026] @AlexBataller et al. #EHA2026 EHA-4897 PF656 library.ehaweb.org/eha/2026/eha-2… #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI

Virtual, Sustained Smoking Cessation Program for Cancer Patients Doubles Quitting Rate, Clinical Trial Shows [7/13/26] - @MassGenBrigham @MassGeneralNews RE: EAQ171CD #NCT03808818 @PsycholERPark et al. @JCO_ASCO massgeneralbrigham.org/en/about/newsr… @eaonc

Join us for a showcase of Tempus Lens’ latest co-scientist capabilities in action, including new AI agents and advanced tools designed to accelerate your analysis. Katie Igartua, PhD, will be joined by Shelley MacNeil, PhD, Olivier Harismendy, Ph.D. and Xiaolin Zhu, MD, PhD, to explore the real-world impact of our AI-enabled platform through peers’ research and how our extensive multimodal data can help advance the next scientific breakthrough. Register now: tempus.co/4bnuwyg

OMB’s proposed overhaul of federal grant rules drew nearly HALF A MILLION public comments led by the scientific community - an extraordinary response and, as far as I can tell - among the largest public comment dockets ever for an OMB rulemaking.

Join us for an upcoming webinar to hear Holly LaDuca, MS, CGC, Thomas Slavin, MD, MBA and Alan Tan, MD, discuss actionable strategies and overcoming barriers for integrating germline testing into your practice. This live session will explore current clinical guidelines on appropriate candidates for germline testing and how germline results can directly influence personalized treatment selection, surgical decisions, and other aspects of care. Register here: tempus.co/4vQJc15

Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program [July 13, 2026] @PsycholERPark et al. @JCO_ASCO ascopubs.org/doi/10.1200/JC… #NCORP @eaonc

The Art of Oncology Contest is Back! We invite trainees and early-career oncologists to share personal, empathetic essays on the human side of cancer care. Reflect on your journey & inspire your peers. Deadline is August 27, 2026. Share your story and submit today: bit.ly/4bgUyTK

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act [7/2017] Kehl et al. @DavidHongMD @CCR_AACR ow.ly/TsUu30jCe7L #caxtx #hpeonc

Reaffirming & Clarifying @ASCO Policy Statement on Phase I #ClinicalTrials [Nov 28, 2016] Weber et al. @JCO_ASCO ow.ly/QxVh306TREf #ClinicalTrials #ctsm

Initiative to Modernize Eligibility Criteria for #ClinicalTrials Launched [May 17, 2016] - @ASCO in Action ow.ly/fGrq300pMAd

Modernizing Eligibility Criteria for Molecularly Driven #ClinicalTrials [Jul 20, 2015] - @EdKimMDLCI et al. @JCOOP_ASCO ow.ly/RGEdG #PrecisionMedicine

"The ACA requires payers to cover routine patient costs in phase I to IV trials." [2014] Weber et al. @JCO_ASCO ow.ly/9IFu30aGyh3 #ClinicalTrials #ctsm

...position of @ASCO that phase 1 cancer clinical trials have therapeutic intent & should be covered by Medicare [2014] Weber et al. @lynn_schuchter @JCO_ASCO ow.ly/9IFu30aGyh3 #ClinicalTrials #ctsm

.@ASCO Policy Statement Update: Critical Role of Phase I Trials in Cancer Research & Tx [2014] Weber et al. @lynn_schuchter @JCO_ASCO ow.ly/9IFu30aGyh3 #ClinicalTrials #ctsm

85% of cancer patients are treated in community setting [2003; Feb 23, 2009 online] @GaryCohenMD @CAonline ow.ly/eLaUJ #ClinicalTrials #NCORP

"Without clinical trials, cancer treatment would always remain the same" [Nov 3, 2012] - via @TomBeer in @OncologyTimes ow.ly/fmaKk #ClinicalTrials #ctsm

Early-Phase #ClinicalTrials In The Community: Results From the NCCCP Early Phase Working Group (EPWG) [2012] Zaren et al. @JCOOP_ASCO ow.ly/AmoFc #NCORP

1971 Bipartisan support "to strengthen @theNCI & @NIH in order to conquer cancer as soon as possible" ow.ly/L1C07 #ClinicalTrials HT @jghoggatt

European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation businesswire.com/news/home/2026… Learn more 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ColorectalCancer #Erbitux | @skopetz | @OncBrothers | @realbowtiedoc | @SuyogCancer | @YJanjigianMD

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trial… #mmsm #bmtsm

EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous clinicaltrials.gov/study/NCT07085… #NCT07085728 #mmsm @eaonc